11 results
8-K
EX-99.1
VBIV
VBI Vaccines Inc.
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
sustainable growth and value for key stakeholders – patients, healthcare providers, and shareholders.”
Recent Key Program Achievements and Projected
8-K
EX-99.1
VBIV
VBI Vaccines Inc.
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm
for biotechnology companies, we are intensely focused on managing our operating expenses and capital to fuel sustainable growth and value for key
8-K
EX-99.1
VBIV
VBI Vaccines Inc.
15 May 23
VBI Vaccines Reports First Quarter 2023 Financial Results
8:00am
significant unmet needs with meaningful near-term milestones, and (3) managing our operational expenses and capital to fuel sustainable growth and value
8-K
EX-99.1
VBIV
VBI Vaccines Inc.
6 Dec 22
Entry into a Material Definitive Agreement
9:25am
at risk including in low-income and middle-income countries, at a low but commercially sustainable price. VBI also agrees to continue to sell
8-K
rqmwb64dq83zedp
10 Mar 21
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
7:38am
8-K
EX-99.1
tmccsalxr
2 Nov 20
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update
11:31am
6-K
EX-99.1
lfu2iuj4d
23 Oct 14
Current report (foreign)
12:00am
6-K
EX-99.1
qsrk4o41o
3 Aug 12
June 2012 Mineral Resource Update
12:00am
6-K
EX-99.1
q3zjajb6
19 Mar 12
Current report (foreign)
12:00am
- Prev
- 1
- Next